EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Application of Immuno-PET in Antibody–Drug Conjugate Development

Kendra S Carmon, Ali Azhdarinia

Molecular Imaging · 01.01.2018 · 17

DOI: 10.1177/1536012118801223 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecular Imaging, online erschienen am 29.10.2018. Verfasst von Kendra S Carmon und 1 weiteren Autor:innen. Beteiligte Einrichtung: 1 Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA. Hauptthemen laut MEDLINE: Positron-Emission Tomography. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: John S. Dunn Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted therapies hold great promise for cancer treatment and may exhibit even greater efficacy when combined with patient selection tools. The clinical impact of identifying likely responders includes reducing the number of unnecessary and ineffective therapies as well as more accurately determining drug effects. Positron emission tomography (PET) imaging using zirconium-89 radiolabeled monoclonal antibodies (mAbs), also referred to as zirconium-89 ( 89 Zr)-immuno-PET, provides a potential biomarker to measure target expression and verify optimal delivery of targeted agents to tumors. Antibody–drug conjugates (ADCs) combine the high affinity and specificity of mAbs with the potency of cytotoxic drugs to target tumor-expressing antigen and destroy cancer cells. Thus, 89 Zr-immuno-PET of whole-body biodistribution, pharmacokinetics, and tumor targeting of antibodies and ADCs to predict toxicity and efficacy could help guide individualized treatment. Here, we review how 89 Zr-immuno-PET is being used as a companion diagnostic with the development of ADCs. Furthermore, we discuss how 89 Zr-immuno-PET may be utilized in future clinical trials as an adjunct tool with novel ADCs to select cancer patients who have the greatest potential to benefit from treatment and improve ADC dosing regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyAnimalsAntigensDrug Delivery SystemsHumansImmunoconjugatesNeoplasms

Stichwörter der Autor:innen

antibody–drug conjugatescancercompanion diagnosticsimmuno-PETmolecular imaging

Substanzen

AntigensImmunoconjugates

Autor:innen und Institutionen

  • 1 Institute of Molecular Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.

Förderung

  • John S. Dunn Foundation

Zitieren

APA

Carmon, K. S., & Azhdarinia, A. (2018). Application of Immuno-PET in Antibody–Drug Conjugate Development. Molecular Imaging, 17. https://doi.org/10.1177/1536012118801223

Vancouver

Carmon KS, Azhdarinia A. Application of Immuno-PET in Antibody–Drug Conjugate Development. Molecular Imaging. 2018;17. doi:10.1177/1536012118801223

BibTeX
@article{Carmon2018,
  author = {Carmon, Kendra S and Azhdarinia, Ali},
  title = {Application of Immuno-PET in Antibody–Drug Conjugate Development},
  journal = {Molecular Imaging},
  year = {2018},
  volume = {17},
  doi = {10.1177/1536012118801223}
}
Kostenlos starten →